FREQUENTLY ASKED ~ PT-141
PT-141 questions, answered from the record.
Direct answers on what bremelanotide is, whether it works, how it acts, what it is approved for, and what the label says about dose — each cited where it states a number.
Does PT-141 work?
In the two identical Phase 3 RECONNECT trials in premenopausal women with HSDD, bremelanotide met both coprimary endpoints versus placebo [3]. The benefit was statistically significant but clinically modest, and a published re-analysis disputes its real-world size [9]. Outside that approved indication, there is no Phase 3 efficacy answer.
What were the results of the PT-141 clinical trials?
RECONNECT (n=1,267) reported an integrated FSFI-desire change of +0.35 (P<.001) and an FSDS-DAO item-13 change of -0.33 (P<.001) versus placebo over 24 weeks [3]. A 52-week open-label extension sustained the effect, with nausea, flushing, and headache the most common adverse events [4].
What are the benefits of PT-141?
In its approved population — premenopausal women with HSDD — trials documented improved sexual desire and reduced desire-related distress versus placebo; the magnitude was modest [3]. All male and erectile benefits are off-label and investigational, not established [1].
How big is the effect of bremelanotide on sexual desire?
The integrated Phase 3 effects were small: FSFI-desire +0.35 and FSDS-DAO item-13 -0.33 [3]. A published re-analysis argued these benefits, while statistically significant, are of questionable clinical meaningfulness — that is, possibly too small to be noticed in daily life [9].
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide and melanocortin (MC3R/MC4R) receptor agonist that acts centrally in the brain on the circuitry of sexual desire [1]. It is FDA-approved for one indication only [6].
What is PT-141 peptide?
It is a cyclic heptapeptide — a ring of seven amino acids — and an analogue of the natural hormone alpha-MSH [1]. The cyclic structure gives it greater stability than the straight-chain melanocortin peptides it is related to.
What does the PT-141 peptide do?
It activates central melanocortin receptors (chiefly MC4R) in hypothalamic and limbic circuits, engaging dopamine pathways tied to sexual motivation [1]. It does not act on vascular blood flow the way erection drugs do — its action is in the brain [1].
What is PT-141 used for?
Bremelanotide is FDA-approved (2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [6]. Every other use — in men, for erectile dysfunction, in postmenopausal women — is off-label and not covered by that approval.
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the research and development designation; bremelanotide is the international nonproprietary name for the same molecule and the name on its approved label [6]. They are one compound under two names.
What is bremelanotide?
Bremelanotide is the approved-drug name for PT-141: a melanocortin receptor agonist approved as a 1.75 mg subcutaneous as-needed injection for HSDD in premenopausal women [6][11]. It acts on central brain circuits, not on blood vessels [1].
How does PT-141 work?
It stimulates MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, engaging dopamine signalling linked to sexual desire [1]. This is a central mechanism, unlike PDE-5 inhibitors, which act on peripheral blood vessels [1].
What receptors does PT-141 act on?
Primarily the melanocortin 4 receptor (MC4R), and secondarily the melanocortin 3 receptor (MC3R), both concentrated in the central nervous system [1]. These are the brain-side members of the five-receptor melanocortin family.
Does PT-141 work through the brain or through blood flow?
Through the brain. It acts centrally on melanocortin receptors in sexual-motivation circuits; it does not act on vascular smooth muscle the way PDE-5 inhibitors do [1]. A human fMRI study confirmed it alters central processing of erotic cues [5].
What is a melanocortin receptor agonist?
A drug that activates melanocortin receptors (MC1R-MC5R), a family of G-protein-coupled receptors that respond to peptides such as alpha-MSH [1]. PT-141 targets the central MC3R/MC4R subtypes, which is why its effect is on desire rather than blood flow.
Does PT-141 increase testosterone?
No. PT-141 does not act through the HPG axis and does not directly raise testosterone [12]. Its effect on sexual desire runs through central melanocortin signalling — a common misconception worth correcting [1].
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow; PT-141 acts centrally on the brain's sexual-desire circuitry [1]. The two mechanisms are distinct, which is exactly why combination research exists [13].
What is the PT-141 dosage?
Reported as a finding only: the approved label specifies bremelanotide 1.75 mg subcutaneously as needed, no more than one dose per 24 hours and no more than eight doses per month [11]. This is not a protocol for any reader to follow.
How much PT-141 should I take?
This site does not recommend a dose. It reports trial and label figures: the approved as-needed dose in the studied population was 1.75 mg subcutaneous, with strict frequency limits [11]. Any decision about use belongs with a qualified clinician, not a website.
How much PT-141 to inject?
The approved label figure is 1.75 mg subcutaneous as needed; Phase 2 dose-finding evaluated 0.75, 1.25, and 1.75 mg [8][11]. These are reported as research findings, not as guidance to self-administer.
What is the PT-141 dosage for women?
In the approved premenopausal-HSDD indication, the label dose is bremelanotide 1.75 mg subcutaneous as needed (maximum one per 24 hours, eight per month) [11]. Reported as a label fact, not a recommendation.
How do you reconstitute PT-141?
The approved finished drug is a pre-filled autoinjector and is not reconstituted [11]. Material sold as a "PT-141 research chemical" is a separate, laboratory-only product; this site does not provide reconstitution or self-administration instructions.
How do you take PT-141?
In trials and on the label, bremelanotide is given subcutaneously, as needed, at least 45 minutes before anticipated activity [11]. Early research also used intranasal and intravenous routes; intranasal was discontinued for pharmacokinetic variability [1]. Reported as findings, not instructions.